These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder. Funakoshi K; Suzuki K Neurol Sci; 2023 Mar; 44(3):1097-1098. PubMed ID: 36350454 [No Abstract] [Full Text] [Related]
44. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review. Tao S; Zhang Y; Ye H; Guo D Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657 [TBL] [Abstract][Full Text] [Related]
53. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S; Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418 [TBL] [Abstract][Full Text] [Related]
54. Sarilumab: First Global Approval. Scott LJ Drugs; 2017 Apr; 77(6):705-712. PubMed ID: 28290137 [TBL] [Abstract][Full Text] [Related]
55. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202 [TBL] [Abstract][Full Text] [Related]
56. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267 [TBL] [Abstract][Full Text] [Related]
57. New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD. Takeshita Y; Fujikawa S; Serizawa K; Fujisawa M; Matsuo K; Nemoto J; Shimizu F; Sano Y; Tomizawa-Shinohara H; Miyake S; Ransohoff RM; Kanda T Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34667128 [TBL] [Abstract][Full Text] [Related]
58. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders. Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018 [TBL] [Abstract][Full Text] [Related]
59. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia. Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527 [TBL] [Abstract][Full Text] [Related]
60. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future. Lin J; Xue B; Li X; Xia J Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]